Indoor Cycling Three Times a Week Targets CVD Risk Factors in Women With Obesity
A 3-month interval cycling program assessed cardiovascular and metabolic improvements in obese vs. normal-weight women.
Summary
Researchers at Poznan University enrolled 31 women — 23 with obesity and 8 with normal weight — in a 12-week indoor cycling program featuring three 55-minute sessions per week. The interval-based protocol pushed participants to 65–95% of maximum heart rate, with high-intensity bursts exceeding 80% HRmax. The study tracked a broad panel of cardiometabolic markers including blood pressure, lipid profiles, oxidized LDL, inflammatory markers like CRP, vascular endothelial function indices such as eNOS and VEGF, and body composition via DXA. The goal was to determine whether structured cycling could close the cardiovascular risk gap between obese and normal-weight women. This completed trial offers clinicians practical evidence supporting indoor cycling as a structured, scalable tool for managing obesity-related CVD risk in middle-aged women.
Detailed Summary
Cardiovascular disease remains the leading cause of death in women, with obesity amplifying nearly every major risk factor — from hypertension and dyslipidemia to endothelial dysfunction. Finding accessible, evidence-based exercise interventions that specifically target these pathways is a clinical priority, particularly for sedentary or overweight women who may not tolerate high-impact training.
This completed prospective trial enrolled 31 women aged 34–62 from Poznan, Poland. Twenty-three had obesity (BMI ≥30, waist circumference >80 cm) and eight had normal body weight (BMI 18.5–24.9). Both groups completed the same 3-month indoor cycling program — 36 sessions total, three per week — using Schwinn ergometers with heart rate monitoring. Sessions ran approximately 55 minutes and centered on interval training at 65–95% HRmax, with repeated high-intensity bursts exceeding 80% HRmax interspersed with active recovery.
Outcome measures were extensive: anthropometrics, DXA body composition, isokinetic muscle strength, VO2 peak via graded exercise testing, resting and exercise blood pressure, and a full cardiometabolic biomarker panel. Vascular function markers included eNOS and VEGF (endothelial health) alongside TBARS and TAS (oxidative stress). Lipid panels captured total cholesterol, LDL, HDL, triglycerides, and oxidized LDL. Dietary intake was controlled and monitored throughout via structured interviews.
Full results are not reported in the available abstract, but the trial was designed with adequate statistical power (80%) to detect meaningful changes in VO2 peak. The hypothesis was that cycling could shift obese women's cardiometabolic profiles toward those of normal-weight peers — a clinically meaningful target.
For clinicians, this trial supports interval-based indoor cycling as a practical, low-barrier intervention for women with metabolic risk. The structured heart rate targeting and comprehensive biomarker panel make it a useful model for real-world exercise prescription. Limitations include small sample size, short duration, and abstract-only data availability.
Key Findings
- A 3-month indoor cycling program targeting 65–95% HRmax was tested in obese and normal-weight women.
- The protocol included 36 sessions with high-intensity intervals exceeding 80% HRmax to maximize cardiometabolic stimulus.
- Outcome panel included eNOS, VEGF, oxidized LDL, CRP, lipids, and DXA body composition — unusually comprehensive.
- Dietary intake was controlled and monitored, strengthening the ability to attribute changes to exercise alone.
- Trial was adequately powered for VO2 peak as primary endpoint, lending statistical credibility to results.
Methodology
Prospective exercise intervention trial comparing 23 obese and 8 normal-weight women over 12 weeks, with 36 supervised indoor cycling sessions. Heart rate was continuously monitored; diet was assessed and held constant. Comprehensive biomarker and body composition assessments performed at baseline and post-intervention.
Study Limitations
The sample size is small (31 total, only 8 in the normal-weight control group), limiting statistical power for secondary endpoints. This summary is based on the abstract only; full results, effect sizes, and specific biomarker changes are not available. The 3-month duration may be insufficient to capture sustained cardiovascular remodeling.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.